Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Oktober 2025 18:05 ET | Quelle: AdvanCell

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025

AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025 Results from the Phase 1b dose escalation of the...
28. Oktober 2024 10:00 ET | Quelle: HOPO Therapeutics, Inc.

HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity

HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity